Do you have psoriasis?

The POETYK study: A clinical trial to assess a new drug for psoriasis

Psoriasis is a chronic inflammatory skin disorder, characterised primarily by scaly plaques, that affects up to 3% of the general population. Many patients with severe disease are still being managed with only topical treatments, and many patients consider their psoriasis treatment to be inadequate.

The purpose of this research project is to measure how safe and effective BMS-986165 (the investigational drug) is in treating participants with moderate-to-severe plaque psoriasis. Prior research studies have shown that BMS-986165 may help control the immune system that is responsible for the signs and symptoms of psoriasis by controlling the molecules in the body responsible for inflammation within the skin.

Anticipated date that enrolment will close: TBA

Who can take part

Inclusion criteria:

  • Adults over the age of 18
  • Diagnosis of plaque psoriasis for 6 months or more

Exclusion criteria

  • Non-plaque psoriasis
  • Evidence of active infection, including TB
  • Recent surgeries in the last 8 weeks
  • Unstable medical and psychiatric conditions

What is involved for you

  • approximately 18 visits
  • chest x-ray
  • blood/urine samples
  • weight
  • blood pressure
  • skin checks
check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
2018.207
Annette Phemister
03 9342 4531